In a recent development in the ongoing legal battle over COVID-19 vaccine patents, Pfizer and BioNTech have requested the Patent Trial and Appeal Board (PTAB) to dismiss Moderna’s arguments that are based on the timing of district court patent litigation. This action has arisen out of Pfizer’s challenges to two of Moderna’s COVID vaccine patents.
The pharmaceutical firms contend that Moderna’s arguments rely on “cherry-picked data” and that the biotech company is acting “willfully naïve” in its conduct.
This legal confrontation is but one face of a complex global issue involving intellectual property rights pertaining to COVID-19 vaccines. Legal professionals across the globe are paying close attention to not only the outcome of these disputes, but also the implications they may carry for future vaccine-related patent contestations and overall IP regulation.